Allergan Recalls Lumigan Bimatoprost Ophthalmic Solution Due to Impurities
Allergan is recalling 153,616 bottles of Lumigan (bimatoprost) 0.01% ophthalmic solution because the product failed impurities and degradation specifications.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The FDA classified this as a Class III recall, which by definition is unlikely to cause adverse health consequences, fitting the 'Low' severity criteria for documentation or minor specification failures without reported harm.
Plain-English summary
Allergan Sales, LLC is recalling 153,616 bottles of Lumigan (bimatoprost ophthalmic solution) 0.01%, 2.5 mL bottles. The recall is due to the product failing impurities and degradation specifications. The affected product is identified by Lot # 92575 with an expiration date of JUN-2018 and NDC# 0023-3205-03.
The recalled product was distributed nationwide and in Barbados, Curacao, Dominican Republic, Guyana, Jamaica, and Trinidad and Tobago. The FDA has classified this recall as Class III, indicating that use of or exposure to the violative product is not likely to cause adverse health consequences.
Consumers and healthcare providers should stop using the affected product and return it to the pharmacy or point of purchase for a refund or replacement. Patients should consult their healthcare provider for alternative treatment options if necessary.
The recalled product
- Product
- LUMIGAN (BIMATOPROST)
- Brand
- LUMIGAN
- Manufacturer
- Allergan Sales, LLC
- Category
- Drug — Ophthalmic Solution
- Hazard
- Affected units
- 153,616
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot #: 92575 Exp. JUN-2018
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by Allergan Sales, LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · LUMIGAN
- LowAllergan Recalls Lumigan Bimatoprost Ophthalmic Solution Due to Impurity Failures
FDA (Drugs) · 2017-04-19
Same manufacturer · Allergan Sales, LLC
See all →- HighKeller Funnel 2 breast implant insertion devices recalled for potential coating defect
FDA (Devices) · 2024-05-08
- ModerateAllergan Recalls 72 Bottles of Combigan Eye Drops for cGMP Deviations
FDA (Drugs) · 2019-04-03
- LowAllergan Recalls Combigan Eye Drops Due to Failed Impurity Specifications
FDA (Drugs) · 2017-11-22
- SevereAllergan Recalls Blephamide Ophthalmic Ointment Due to Impurity Failures
FDA (Drugs) · 2017-07-05
- ModerateAllergan Recalls Tazorac Gel 0.05% Due to Content Uniformity Failures
FDA (Drugs) · 2016-10-19
Same hazard · impurities
See all →- LowDabigatran Etexilate Capsules Recalled Due to Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- ModerateGlycopyrrolate Oral Solution Recalled Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-29
- ModerateMethohexital Sodium for Injection Recalled for Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-15
- ModerateMethohexital Sodium 100 mg/10 mL Compounded Drug Recalled Nationwide
FDA (Drugs) · 2026-07-15
- LowFexofenadine Hydrochloride Tablets 180 mg Recalled for Impurities
FDA (Drugs) · 2026-07-08